As reported on Healthline, a man in Norway has entered sustained HIV remission following a stem cell transplant, becoming one of a small number of individuals worldwide to achieve what researchers describe as a “functional cure.” The case strengthens scientific understanding of how HIV eradication might be possible under specific biological and immune conditions, though the approach remains unsuitable for use as a broad treatment strategy.
A rare but informative outcome
The patient, known in the literature as the “Oslo patient,” is a 63-year-old man who underwent an allogeneic hematopoietic stem cell transplant (HSCT) to treat myelodysplastic syndrome, a bone marrow disorder. Five years after the procedure, extensive testing of his blood, gastrointestinal tissue, and bone marrow revealed no measurable HIV reservoirs, confirming durable remission without the need for ongoing antiretroviral therapy.
The case was recently reported in Nature Microbiology and is notable as the first documented instance of HIV remission following a stem cell donation from a sibling.
Functional cure versus eradication
HIV, if untreated, progressively damages immune function and can lead to AIDS. While modern prevention methods such as pre-exposure prophylaxis (PrEP) and lifelong antiretroviral therapy (ART) have transformed HIV into a manageable chronic condition, they do not eliminate the virus entirely. HIV persists by remaining dormant in long-lived immune cells, forming reservoirs that allow viral rebound if treatment stops.
A “functional cure” refers to long-term viral suppression without therapy, even though trace amounts of virus may still exist at levels too low to reignite infection.
The role of CCR5Δ32 genetics
Most prior cases of HIV remission after HSCT have shared a critical feature: donor stem cells carried a rare genetic alteration known as the CCR5Δ32 mutation. This mutation prevents expression of the CCR5 receptor on immune cells, a primary pathway HIV uses to enter and infect them.
The Oslo patient received stem cells from a brother who inherited two copies of this mutation, rendering the donor cells highly resistant to HIV. Only about 3% of people globally carry the mutation, with higher prevalence in Northern European populations.
Experts emphasize, however, that genetics alone does not fully explain remission. Each successful case appears to involve a complex interaction of immune replacement, viral resistance, and post-transplant immune activity.
Immune-mediated clearance of HIV
HSCT requires intensive chemotherapy or radiation to destroy the patient’s existing immune system before donor cells are infused to rebuild it. This process drastically reduces the pool of cells capable of harboring dormant HIV.
Additionally, some patients develop graft-versus-host disease (GVHD), a complication in which donor immune cells attack residual host cells. While GVHD can be dangerous, it may inadvertently help eliminate HIV-infected cells through what researchers call a “graft-versus-reservoir” effect.
Notably, HIV remission has been reported even in transplant recipients whose donors lacked the CCR5Δ32 mutation, suggesting immune-mediated clearance can sometimes compensate for genetic resistance.
Contribution of HIV-active medications
Researchers are also examining the role of drugs commonly used to control GVHD. Medications such as ruxolitinib and vedolizumab may exert anti-HIV effects by further reducing viral reservoirs. At the same time, patients remain on ART during immune recovery, preventing any surviving virus from infecting newly formed immune cells.
Together, immune replacement, targeted immune attack, genetic resistance, and adjunctive drug effects may create a rare but powerful environment in which HIV becomes unable to reestablish infection.
Implications for future HIV research
To date, only about 10 individuals worldwide, ranging from locations including Berlin, London, New York, Geneva, and now Oslo, have been documented as achieving long-term HIV remission after stem cell transplantation. All underwent HSCT for cancers or serious hematologic diseases unrelated to HIV.
Because HSCT carries substantial risks, it is not considered a viable cure strategy for people living with HIV alone. Nonetheless, these cases continue to serve as critical biological case studies, helping researchers identify mechanisms that could someday be replicated with safer, more scalable therapies.
As experts note, each remission case adds another clue to solving one of medicine’s most persistent challenges: how to permanently silence HIV without destroying the immune system to do it.
